ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: TH-PO921

Acute Kidney Dysfunction with No Rejection (ADNR) Is Associated with Poor Outcomes in Kidney Transplant Recipients

Session Information

Category: Transplantation

  • 1702 Transplantation: Clinical and Translational

Authors

  • Paquot, François, University of Liege Hospital (ULg CHU), Liege, Belgium
  • Pottel, Hans, KULeuven, Kortrijk, Belgium
  • Bonvoisin, Catherine, University of Liege Hospital (ULg CHU), Liege, Belgium
  • Weekers, Laurent E., University of Liege Hospital (ULg CHU), Liege, Belgium
  • Jouret, Francois, University of Liege Hospital (ULg CHU), Liege, Belgium
Background

The entity “acute kidney dysfunction with no rejection (ADNR)” has been proposed for kidney transplant recipients (KTR) presenting with acute elevation of serum creatinine without histological evidence of acute rejection (AR). The prognosis of ADNR has not been studied thus far.

Methods

From 2007 to 2015, we retrospectively categorized all KTRs with a for-cause kidney biopsy within 12 months post-kidney transplantation (KTx) into 2 groups: ADNR and biopsy-proven AR. Control group (C) included KTR with no ADNR or AR within 24 months post-KTx. BK virus nephropathy and primary nonfunction were excluded. Estimated glomerular filtration rate (eGFR) was determined using the Modification of Diet in Renal Disease (MDRD) equation. Linear mixed models established intercepts and slopes of eGFR decline from 6 to 24 months post-KTx. Cubic spline analysis calculated the percentage of patients with a ≥30% reduction of eGFR from 6 to 24 months post-KTx.

Results

The mean age (years) at KTx was 50.2±14.2, 47.9±17.8 and 53.6±12.4 for ADNR (n=93), AR (n=22) and C (n=135), respectively. The female/male ratio was 39.8% (ADNR), 45.5% (AR) et 34.1 (C). The rate of delayed graft function was not significantly different among groups, and reached 26.9% (ADNR), 22.7% (AR) and 14.1% (C). The median time for for-cause graft biopsy was 22 [10-70] and 13 [7-43] days post-KTx for ADNR and AR, respectively. Of note, ADNR included 21 (22.6%) patients with "borderline" histology. At 6 months post-KTx, eGFR was higher in C (55.2±1.6 mL/min) vs. ADNR (45.5±1.9 mL/min; p<0.05) and vs. AR (48.6±3.9 mL/min; p, 0.13). The eGFR slope from 6 to 24 months post-Tx was positive in C (0.16±0.06mL/min/month) compared to negative slopes in ADNR (-0.04±0.08mL/min/month, p<0.05) and in AR (-0,04±0.16mL/min/month, p, 0.26). The proportion of KTR presenting with a ≥30% reduction of eGFR from 6 to 24 months post-KTx reached 7.4% in C vs. 25.8% in ADNR (p<0.05) and 19.1% in AR (p<0.05).

Conclusion

In the present monocentric cohort, ADNR occurs frequently and early post KTx, and is associated with a significantly lower eGFR at 6 months and a significantly faster eGFR decline from 6 to 24 months post-KTx, in comparison to controls.

Funding

  • Clinical Revenue Support